Last reviewed · How we verify
POLYGYNAX® — Competitive Intelligence Brief
phase 3
Combination antibiotic and antifungal agent
Infectious Disease / Gynecology
Small molecule
Live · refreshed every 30 min
Target snapshot
POLYGYNAX® (POLYGYNAX®) — Laboratoire Innotech International. POLYGYNAX is a vaginal capsule containing a combination of antibiotics and antifungal agents that eliminates pathogenic bacteria and fungi in the vaginal tract.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| POLYGYNAX® TARGET | POLYGYNAX® | Laboratoire Innotech International | phase 3 | Combination antibiotic and antifungal agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Combination antibiotic and antifungal agent class)
- Laboratoire Innotech International · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- POLYGYNAX® CI watch — RSS
- POLYGYNAX® CI watch — Atom
- POLYGYNAX® CI watch — JSON
- POLYGYNAX® alone — RSS
- Whole Combination antibiotic and antifungal agent class — RSS
Cite this brief
Drug Landscape (2026). POLYGYNAX® — Competitive Intelligence Brief. https://druglandscape.com/ci/polygynax. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab